3NMX
Crystal structure of APC complexed with Asef
Summary for 3NMX
Entry DOI | 10.2210/pdb3nmx/pdb |
Related | 3NMW 3NMZ |
Descriptor | APC variant protein, Rho guanine nucleotide exchange factor 4 (3 entities in total) |
Functional Keywords | protein-protein complex, cell adhesion-cell cycle complex, cell adhesion/cell cycle |
Biological source | Homo sapiens (human) More |
Total number of polymer chains | 6 |
Total formula weight | 125462.68 |
Authors | |
Primary citation | Zhang, Z.,Chen, L.,Gao, L.,Lin, K.,Zhu, L.,Lu, Y.,Shi, X.,Gao, Y.,Zhou, J.,Xu, P.,Zhang, J.,Wu, G. Structural basis for the recognition of Asef by adenomatous polyposis coli. Cell Res., 22:372-386, 2012 Cited by PubMed Abstract: Adenomatous polyposis coli (APC) regulates cell-cell adhesion and cell migration through activating the APC-stimulated guanine nucleotide-exchange factor (GEF; Asef), which is usually autoinhibited through the binding between its Src homology 3 (SH3) and Dbl homology (DH) domains. The APC-activated Asef stimulates the small GTPase Cdc42, which leads to decreased cell-cell adherence and enhanced cell migration. In colorectal cancers, truncated APC constitutively activates Asef and promotes cancer cell migration and angiogenesis. Here, we report crystal structures of the human APC/Asef complex. We find that the armadillo repeat domain of APC uses a highly conserved surface groove to recognize the APC-binding region (ABR) of Asef, conformation of which changes dramatically upon binding to APC. Key residues on APC and Asef for the complex formation were mutated and their importance was demonstrated by binding and activity assays. Structural superimposition of the APC/Asef complex with autoinhibited Asef suggests that the binding between APC and Asef might create a steric clash between Asef-DH domain and APC, which possibly leads to a conformational change in Asef that stimulates its GEF activity. Our structures thus elucidate the molecular mechanism of Asef recognition by APC, as well as provide a potential target for pharmaceutical intervention against cancers. PubMed: 21788986DOI: 10.1038/cr.2011.119 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report